These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 9855176)

  • 1. Future trends in the development of safer nonsteroidal anti-inflammatory drugs.
    Wolfe MM
    Am J Med; 1998 Nov; 105(5A):44S-52S. PubMed ID: 9855176
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual acting anti-inflammatory drugs: a reappraisal.
    Bertolini A; Ottani A; Sandrini M
    Pharmacol Res; 2001 Dec; 44(6):437-50. PubMed ID: 11735348
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gastrointestinal safety and tolerability of nonselective nonsteroidal anti-inflammatory agents and cyclooxygenase-2-selective inhibitors.
    Peura DA
    Cleve Clin J Med; 2002; 69 Suppl 1():SI31-9. PubMed ID: 12086291
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gastrointestinal safety profile of meloxicam: a meta-analysis and systematic review of randomized controlled trials.
    Schoenfeld P
    Am J Med; 1999 Dec; 107(6A):48S-54S. PubMed ID: 10628593
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gastrointestinal effects of nonsteroidal anti-inflammatory drugs.
    Whittle BJ
    Fundam Clin Pharmacol; 2003 Jun; 17(3):301-13. PubMed ID: 12803569
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanisms of nonsteroidal anti-inflammatory drug-induced gastrointestinal injury and repair: a window of opportunity for cyclooxygenase-inhibiting nitric oxide donors.
    Perini R; Fiorucci S; Wallace JL
    Can J Gastroenterol; 2004 Apr; 18(4):229-36. PubMed ID: 15054499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. "Selective" switching from non-selective to selective non-steroidal anti-inflammatory drugs.
    Bennett K; Teeling M; Feely J
    Eur J Clin Pharmacol; 2003 Nov; 59(8-9):645-9. PubMed ID: 12942226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New directions in cyclooxygenase research and their implications for NSAID-gastropathy.
    Flower RJ
    Ital J Gastroenterol; 1996 Dec; 28 Suppl 4():23-7. PubMed ID: 9032578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclo-oxygenase-2 inhibitors and the kidney: a case for caution.
    Noroian G; Clive D
    Drug Saf; 2002; 25(3):165-72. PubMed ID: 11945113
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Review article: COX-II inhibitors--a new generation of safer NSAIDs?
    Donnelly MT; Hawkey CJ
    Aliment Pharmacol Ther; 1997 Apr; 11(2):227-36. PubMed ID: 9146759
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gastrointestinal sparing anti-inflammatory drugs--effects on ulcerogenic and healing responses.
    Takeuchi K; Tanaka A; Suzuki K; Mizoguchi H
    Curr Pharm Des; 2001 Jan; 7(1):49-69. PubMed ID: 11172701
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aspirin and NSAID sensitivity.
    Stevenson DD
    Immunol Allergy Clin North Am; 2004 Aug; 24(3):491-505, vii. PubMed ID: 15242723
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The influence of cyclo-oxygenase specificity of non-steroidal anti-inflammatory drugs on bleeding complications in concomitant coumarine users.
    Knijff-Dutmer EA; Van der Palen J; Schut G; Van de Laar MA
    QJM; 2003 Jul; 96(7):513-20. PubMed ID: 12881594
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical application of cyclooxygenase-2 inhibitors].
    Dzielska-Olczak M; Olczak S
    Pol Merkur Lekarski; 2001 Jun; 10(60):480-2. PubMed ID: 11503270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The gastrointestinal effects of nonselective NSAIDs and COX-2-selective inhibitors.
    Laine L
    Semin Arthritis Rheum; 2002 Dec; 32(3 Suppl 1):25-32. PubMed ID: 12528071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Wound collagen deposition in rats: effects of an NO-NSAID and a selective COX-2 inhibitor.
    Muscará MN; McKnight W; Asfaha S; Wallace JL
    Br J Pharmacol; 2000 Feb; 129(4):681-6. PubMed ID: 10683192
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gastroprotective therapy and risk of gastrointestinal ulcers: risk reduction by COX-2 therapy.
    Wolfe F; Anderson J; Burke TA; Arguelles LM; Pettitt D
    J Rheumatol; 2002 Mar; 29(3):467-73. PubMed ID: 11908558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclooxygenase selectivity and the risk of gastro-intestinal complications of various non-steroidal anti-inflammatory drugs: a clinical consideration.
    Kawai S
    Inflamm Res; 1998 Oct; 47 Suppl 2():S102-6. PubMed ID: 9831331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Preferential COX-2 inhibition: its clinical relevance for gastrointestinal non-steroidal anti-inflammatory rheumatic drug toxicity].
    Dammann HG
    Z Gastroenterol; 1999 Jan; 37(1):45-58. PubMed ID: 10091284
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gastrointestinal toxicity of non-steroidal anti-inflammatory drugs: the effect of nimesulide compared with naproxen on the human gastrointestinal tract.
    Bjarnason I; Thjodleifsson B
    Rheumatology (Oxford); 1999 May; 38 Suppl 1():24-32. PubMed ID: 10369403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.